Analysts See $0.04 EPS for Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Logo

Analysts expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to report $0.04 EPS on February, 26.They anticipate $0.02 EPS change or 100.00 % from last quarter’s $0.02 EPS. IONS’s profit would be $5.50M giving it 362.69 P/E if the $0.04 EPS is correct. After having $-0.03 EPS previously, Ionis Pharmaceuticals, Inc.’s analysts see -233.33 % EPS growth. The stock decreased 0.03% or $0.02 during the last trading session, reaching $58.03. About 764,517 shares traded. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has risen 1.50% since February 8, 2018 and is uptrending. It has outperformed by 1.50% the S&P500.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company has market cap of $7.98 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: which released: “Premarket analyst action – healthcare – Seeking Alpha” on August 07, 2018, also with their article: “Ionis (IONS) Beats Both Earnings & Revenues in Q4 – Nasdaq” published on February 27, 2018, published: “Cannabix Technologies Completes Breath Collection Unit and Provides Update – Nasdaq” on January 28, 2019. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: and their article: “Biogen’s $1 Billion Bet on Ionis – The Motley Fool” published on April 30, 2018 as well as‘s news article titled: “Ionis: Built To Last – Seeking Alpha” with publication date: November 12, 2018.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.